New — Free Peptide Starter Guide (2026): 13 chapters, 34 cited studies

Get it free
ToolsCompareVesilute vs KPV

Vesilute vs KPV

Side-by-side comparison of key properties, dosing, and research.

Anti-Aging & Longevity
Vesilute
Immune SupportRecovery & Repair
KPV
Summary
Vesilute is a tetrapeptide bioregulator (Lys-Glu-Asp-Leu) developed by Professor Vladimir Khavinson, tissue-specific for the retina and visual system. It supports retinal cell function, promotes normalization of photoreceptor protein synthesis, and is studied for age-related macular degeneration (AMD), retinal aging, and vision preservation in the elderly.
KPV is a naturally occurring anti-inflammatory tripeptide derived from the C-terminal of alpha-MSH. It powerfully suppresses intestinal and systemic inflammation via melanocortin receptors, making it valuable for IBD, gut healing, and wound repair.
Half-Life
Short (minutes); sustained gene-regulatory effects
Short half-life (~15–30 minutes), but effects persist longer due to receptor-level anti-inflammatory cascades
Admin Route
SubQ, Oral
Oral, SubQ, Topical
Research
Typical Dose
10 mg per day
500 mcg – 1 mg
Frequency
Daily for 10–30 days
Once to twice daily
Key Benefits
  • Supports retinal photoreceptor cell function and survival
  • May slow progression of age-related macular degeneration
  • Reduces retinal cell apoptosis from oxidative stress and aging
  • Anti-aging effects on retinal pigment epithelium
  • Potential support in diabetic retinopathy management
  • Preserves visual acuity with aging
  • Complementary to lutein, zeaxanthin, and NAD+ in ocular health protocols
  • Reduces intestinal inflammation (IBD, Crohn's, colitis)
  • Promotes gut mucosal healing and barrier integrity
  • Accelerates wound healing topically
  • Suppresses systemic inflammatory cytokines
  • Antimicrobial properties against pathogens
  • Reduces neuroinflammation when administered systemically
  • May improve symptoms of inflammatory skin conditions
Side Effects
  • Generally well tolerated
  • Mild injection site reactions
  • No significant ocular adverse events reported at standard doses
  • Generally very well tolerated
  • Mild injection site reactions (SC)
  • Rare: transient flushing
Stacks With